Melanie Sena is community editor of Pharmaceutical Technology.
Bristol-Myers Squibb Company and Samsung BioLogics announced the companies have entered into a 10-year agreement.
Bristol-Myers Squibb Company and Samsung BioLogics announced the companies have entered into a 10-year agreement under which Samsung BioLogics will manufacture a commercial antibody cancer drug for Bristol-Myers Squibb at its recently completed plant in Songdo Incheon, South Korea. Financial terms were not disclosed. Technology transfer and trial production will commence in July 2013 and commercial production will immediately begin following regulatory approvals.
